|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.34 USD | -1.93% |
|
-10.57% | +49.99% |
| 05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
| 05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
Aeglea BioTherapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was USD 2.33 million compared to USD 18.74 million a year ago. Net loss was USD 83.82 million compared to USD 65.8 million a year ago.
Basic loss per share from continuing operations was USD 24.75 compared to USD 25 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +49.99% | 1.33B | |
| +9.75% | 118B | |
| +9.88% | 106B | |
| -11.13% | 23.4B | |
| -1.69% | 22.1B | |
| -10.23% | 18.34B | |
| -41.92% | 16.59B | |
| -15.69% | 15.97B | |
| +6.72% | 14.03B | |
| +17.31% | 11.67B |
SPYRE THERAPEUTICS, INC. 
